Viridian Therapeutics, Inc.
Moat Score — Viridian Therapeutics, Inc.
Total Moat Score
9 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Viridian holds engineered antibody IP across veligrotug and its half-life-extended sibling elegrobart, plus FDA Breakthrough Therapy designation for veligrotug in thyroid eye disease. This is real, defensible science, but it arrives second to Amgen's already-approved Tepezza, so the IP protects a position rather than a category-defining monopoly. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-commercial biotech with no manufactured product on the market, Viridian has no cost-of-goods or scale advantage over Amgen or any other TED/FcRn competitor; its spending is almost entirely R&D and now commercial build-out costs, not production economics. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | If approved, veligrotug would enter a rare-disease category where Tepezza has already established very high per-course pricing (hundreds of thousands of dollars), giving Viridian real pricing power by category precedent even before launch — though as a second entrant it will likely need to compete on net price or convenience rather than set the market's ceiling. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in antibody therapeutics; more patients on veligrotug do not make the drug more effective or valuable to the next patient or prescriber. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | With no product launched yet, Viridian has not established prescriber or infusion-center switching costs; any such lock-in (patient stability on therapy, established infusion workflows) would only begin to build after a 2026 launch. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Thyroid eye disease is a genuine rare-disease niche that realistically supports only a small number of profitable entrants, which somewhat limits future competition, but Viridian is deliberately targeting that niche as a second mover rather than benefiting from being the incumbent who already captured it. |